Managing pediatric patients with psoriasis

Susan Bard, Daniele Torchia, Lawrence A. Schachner

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Childhood-onset psoriasis affects approximately one-third of the psoriatic population. Among many potential treatments of childhood psoriasis, biological agents are emerging as a valuable option in the management of this disease. In Europe, etanercept has recently been approved for children aged 8 years and over. Data from a well-designed clinical trial indicate that in children, etanercept effectively reduces psoriasis symptoms, with beneficial effects evident as early as 4 weeks after the initiation of treatment. Etanercept is well tolerated; adverse effects are typically mild to moderate in severity. Early data from other biological agents are promising.

Original languageEnglish (US)
Pages (from-to)15-17
Number of pages3
JournalAmerican Journal of Clinical Dermatology
Issue numberSUPPL. 1
StatePublished - 2010

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Managing pediatric patients with psoriasis'. Together they form a unique fingerprint.

Cite this